$9.2 B

NBIX Mkt cap, 22-Jun-2018

$71.1 M

Neurocrine Biosciences Revenue Q1, 2018
Neurocrine Biosciences Gross profit (Q1, 2018)70.1 M
Neurocrine Biosciences Gross profit margin (Q1, 2018), %98.7%
Neurocrine Biosciences Net income (Q1, 2018)-41.8 M
Neurocrine Biosciences EBIT (Q1, 2018)-37.4 M
Neurocrine Biosciences Cash, 31-Mar-2018175.3 M

Neurocrine Biosciences Financials

Neurocrine Biosciences Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2.9 m19.8 m15 m

Revenue growth, %

(100%)(24%)

R&D expense

39.2 m46.4 m81.5 m94.3 m

General and administrative expense

13.3 m18 m32.5 m68.1 m

Operating expense total

52.6 m64.4 m114 m162.4 m

EBIT

(49.7 m)(64.4 m)(94.2 m)(147.4 m)

EBIT margin, %

(1702%)(477%)(982%)

Net Income

(46.1 m)(60.5 m)(88.9 m)(141.1 m)

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Revenue

19.8 m15 m71.1 m

Cost of goods sold

950 k

Gross profit

70.1 m

Gross profit Margin, %

99%

R&D expense

10.2 m12.2 m16.6 m18.7 m24.4 m23.9 m26.9 m20.9 m51.9 m48.9 m

General and administrative expense

4.2 m4.7 m5.5 m6.6 m11.5 m12 m15 m17.5 m28.1 m58.6 m

Operating expense total

14.4 m16.9 m22.1 m25.3 m35.8 m35.9 m41.8 m38.4 m79.9 m108.5 m

EBIT

(14.4 m)(16.9 m)(2.3 m)(25.3 m)(35.8 m)(20.9 m)(41.8 m)(38.4 m)(79.9 m)(37.4 m)

EBIT margin, %

(12%)(139%)(53%)

Interest expense

7.5 m

Net Income

(13.4 m)(15.9 m)(1.2 m)(24 m)(34.4 m)(19.3 m)(40.3 m)(36.9 m)(78.3 m)(41.8 m)

Neurocrine Biosciences Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

44.8 m31 m74.2 m83.3 m

Current Assets

148.5 m198.2 m384.1 m310.4 m

PP&E

1.8 m2.5 m3.4 m6.3 m

Total Assets

154.7 m243 m474.8 m365.1 m

Accounts Payable

101 k246 k2.6 m5.1 m

Current Liabilities

11.7 m15.7 m25.7 m30.4 m

Total Liabilities

50.2 m

Additional Paid-in Capital

886.1 m1 b1.3 b1.4 b

Retained Earnings

(765.8 m)(826.3 m)(915.2 m)(1.1 b)

Total Equity

120.4 m208.7 m424.5 m314.9 m

Financial Leverage

1.3 x1.2 x1.1 x1.2 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Cash

37.4 m29 m170.3 m132.1 m66.4 m115.3 m86.2 m99.8 m64.1 m175.3 m

Accounts Receivable

44.6 m

Current Assets

197.6 m183.9 m405 m389.4 m382.8 m401 m392 m357.9 m239.5 m513.7 m

PP&E

2.2 m2.3 m2.5 m2.8 m2.9 m3.9 m5.8 m6.2 m7.1 m11.8 m

Total Assets

269.5 m257.8 m527.8 m511.2 m492.4 m459.3 m429.8 m399.2 m289.4 m806.4 m

Accounts Payable

846 k900 k1.3 m1 m1.2 m2.1 m1.8 m1.7 m852 k45.7 m

Current Liabilities

12.1 m14 m15.2 m17.6 m19.8 m23.3 m26.9 m26.7 m23.6 m46.5 m

Total Liabilities

441.9 m

Preferred Stock

Additional Paid-in Capital

1 b1 b1.3 b1.3 b1.3 b1.3 b1.4 b1.4 b1.4 b1.6 b

Retained Earnings

(791 m)(806.9 m)(827.5 m)(851.5 m)(885.9 m)(934.5 m)(974.8 m)(1 b)(1.1 b)(1.2 b)

Total Equity

236.8 m224 m484.7 m466.9 m446.9 m413 m381 m351.7 m247.1 m364.5 m

Financial Leverage

1.1 x1.2 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x2.2 x

Neurocrine Biosciences Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(46.1 m)(60.5 m)(88.9 m)(141.1 m)

Depreciation and Amortization

671 k827 k1 m1.5 m

Cash From Operating Activities

(29.6 m)(47.1 m)(38 m)(106.2 m)

Purchases of PP&E

(545 k)(1.6 m)(1.9 m)(4.1 m)

Cash From Investing Activities

5.3 m(105.4 m)(195.8 m)112.9 m

Cash From Financing Activities

5.3 m138.7 m277 m2.4 m

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(13.4 m)(15.9 m)(1.2 m)(24 m)(34.4 m)(19.3 m)(40.3 m)(36.9 m)(78.3 m)(41.8 m)

Depreciation and Amortization

786 k

Accounts Receivable

(13.5 m)

Accounts Payable

846 k900 k1.3 m1 m1.2 m2.1 m1.8 m1.7 m852 k(7.9 m)

Cash From Operating Activities

(38.5 m)

Purchases of PP&E

(1.8 m)

Cash From Investing Activities

(57.1 m)

Cash From Financing Activities

16.1 m

Neurocrine Biosciences Ratios

USDY, 2018

Financial Leverage

2.2 x
Report incorrect company information